Horizon Discovery Group has licensed out access to its bioproduction cell lines in a deal worth a minimum of £500,000.

Under the deal, the first of its kind signed by the Cambridge gene-editing giant, the unnamed partner will gain immediate access to one of Horizon's cutting-edge engineered cell lines for an indefinite period of time in order to manufacture their novel therapeutics.

Dr Darrin Disley, CEO of Horizon Discovery Group, said: “Horizon continues to be a disruptive influence in the bioproduction arena, using technical and commercial innovation to accelerate advancements in drug manufacturing. This new announcement further validates our approach, with our Partner demonstrating their confidence by making a five year commitment via subscription model to the program.

"We look forward to making further announcements in this area as Horizon continues its momentum as a key player in the bioproduction space.”